Analyst Ratings For Sabra Health Care REIT
Portfolio Pulse from Benzinga Insights
Sabra Health Care REIT (NASDAQ:SBRA) has received varied analyst ratings over the past three months, with 5 analysts offering ratings ranging from bullish to indifferent. The average 12-month price target has increased to $15.8, up 12.86% from the previous target of $14.00. Analysts from Mizuho, Stifel, Wells Fargo, and BMO Capital have raised their price targets and ratings, reflecting positive sentiment towards SBRA's stock. Sabra Health Care REIT, a healthcare facility REIT, has shown a revenue growth of 14.82% as of September 30, 2023, but struggles with below industry average net margin, ROE, and ROA, while maintaining a prudent debt-to-equity ratio of 0.82.
January 03, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have raised their price targets for Sabra Health Care REIT, indicating a bullish sentiment. The average price target is now $15.8, reflecting a potential upside from previous targets. The company's revenue growth is strong, but profitability and efficiency metrics are below industry standards.
The positive revisions in analyst ratings and price targets for SBRA suggest a bullish outlook, which could lead to a short-term increase in stock price. The reported revenue growth supports this optimism. However, the below-average profitability and efficiency metrics may temper the extent of the positive impact. The confidence score reflects the general alignment of analyst sentiment but acknowledges the mixed financial performance indicators.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100